Products: Cancer Tests Based on Epigenetic Biomarkers
Our products are cancer tests that detect characteristic epigenetic changes, i.e., DNA methylations, in cancer cells. These highly informative biomarkers, identified and patented by us, form the basis of our research and development for further IVD tests.
Our goal is to develop cancer diagnostic tests for practical application that are fast, safe, and non-invasive.
GynTect® – The Diagnostic Test for Cervical Cancer
GynTect® enables the simple and reliable detection of methylated DNA regions in cervical smear material. The methylation of the GynTect® biomarkers occurs specifically in cervical cancer or its precursors, but not in healthy cervical tissue. Thus, GynTect® can help clarify whether a treatable tissue change is already present.
ScreenYu Gyn® – The First Step Towards Cervical Carcinoma Screening
ScreenYu Gyn® is the second diagnostic test for cervical cancer diagnostics from Epitype GmbH. This molecular biological cancer test is a further development of GynTect®. For ScreenYu Gyn®, only one biomarker, i.e., a methylated DNA region, is detected in cervical smear samples, along with a control marker. Thus, only one PCR reaction is necessary per smear sample. The assay serves as the basis for developing a test for use in screening.